The estimated Net Worth of Kerri Ann Millar is at least $415 Тысяча dollars as of 21 August 2022. Ms Millar owns over 6,667 units of Cue Biopharma Inc stock worth over $10,112 and over the last 6 years she sold CUE stock worth over $0. In addition, she makes $404,655 as Chief Financial Officer at Cue Biopharma Inc.
Sign up
Ms Millar CUE stock SEC Form 4 insiders trading
Ms has made over 4 trades of the Cue Biopharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she exercised 6,667 units of CUE stock worth $3,934 on 21 August 2022.
The largest trade she's ever made was exercising 7,918 units of Cue Biopharma Inc stock on 23 August 2021 worth over $9,343. On average, Ms trades about 1,712 units every 112 days since 2018. As of 21 August 2022 she still owns at least 17,139 units of Cue Biopharma Inc stock.
You can see the complete history of Ms Millar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Kerri-Ann Millar biography
Kerri-Ann Millar is the Chief Financial Officer at Cue Biopharma Inc.
What is the salary of Ms Millar?
As the Chief Financial Officer of Cue Biopharma Inc, the total compensation of Ms Millar at Cue Biopharma Inc is $404,655. There are 5 executives at Cue Biopharma Inc getting paid more, with Anish Suri having the highest compensation of $4,559,810.
How old is Ms Millar?
Ms Millar is 50, she's been the Chief Financial Officer of Cue Biopharma Inc since . There are 12 older and 7 younger executives at Cue Biopharma Inc. The oldest executive at Cue Biopharma Inc is Frederick Driscoll, 70, who is the Independent Director.
What's Ms Millar's mailing address?
Kerri's mailing address filed with the SEC is C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON, MA, 02135.
Insiders trading at Cue Biopharma Inc
Over the last 7 years, insiders at Cue Biopharma Inc have traded over $1,426,672 worth of Cue Biopharma Inc stock and bought 1,194,685 units worth $5,848,356 . The most active insiders traders include Daniel R Passeri, Aaron G.L. Fletcher и Barry J. Simon. On average, Cue Biopharma Inc executives and independent directors trade stock every 37 days with the average trade being worth of $18,162. The most recent stock trade was executed by Anish Suri on 25 August 2023, trading 4,000 units of CUE stock currently worth $11,040.
What does Cue Biopharma Inc do?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
What does Cue Biopharma Inc's logo look like?
Complete history of Ms Millar stock trades at Cue Biopharma Inc
Cue Biopharma Inc executives and stock owners
Cue Biopharma Inc executives and other stock owners filed with the SEC include:
-
Anish Suri,
President, Chief Scientific Officer -
Daniel Passeri,
Chief Executive Officer, Director -
Daniel R. Passeri M.Sc., MSc., J.D.,
CEO & Director -
Colin Sandercock,
Senior Vice President, General Counsel, Secretary -
Dr. Anish Suri Ph.D.,
Pres & Chief Scientific Officer -
Kerri-Ann Millar,
Chief Financial Officer -
Aaron Fletcher,
Independent Director -
Barry Simon,
Independent Director -
Peter Kiener,
Independent Director -
Frederick Driscoll,
Independent Director -
Frank Morich,
Independent Chairman of the Board -
Cameron Gray,
Independent Director -
Tamar Howson,
Director -
Kenneth Pienta,
Chief Medical Officer -
Kerri-Ann Millar,
Chief Financial Officer -
Dr. Kenneth J. Pienta,
Acting Chief Medical Officer -
Dr. Ronald D. Seidel III, Ph.D.,
Co-Founder -
Dr. Matteo Levisetti M.D.,
Sr. VP of Clinical Devel. -
Dr. Ronald D. Seidel III,
Exec. VP and Head of R&D -
Colin G. Sandercock J.D., MSE,
Sr. VP, Gen. Counsel & Sec. -
George B. Zavoico Ph.D.,
VP of Investor Relations & Corp. Devel. -
Dr. Steven C. Almo,
Co-Founder and Chairman of Scientific & Clinical Advisory Board -
Dr. Rodolfo J. Chaparro,
Co-Founder & Sr. Advisor -
Bethany Mancilla,
SVP and Chief Business Officer -
Ronald D. Iii Seidel,
EVP, Head of R&D -
Christopher A Marlett,
Director -
Anthony Digiandomenico,
Director -
Rodolfo Chaparro,
EVP, Head of Immunology -
Steven L Mcknight,
Director -
Patricia Nasshorn,
Chief Business Officer -
Matteo Levisetti,
Chief Medical Officer -
Michael J Fox,
-
Pamela Garzone,
-
Patrick Verheyen,
-
Lucinda Warren,
CHIEF BUSINESS OFFICER